

DAFTAR PUSTAKA

1. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II Definition and Classification Report. *Ocul Surf.* 2017;15(3):276–83.
2. Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II Epidemiology Report. *Ocul Surf.* 2017;15(3):334–65.
3. Wan KH, Chen LJ, Young AL. Depression and anxiety in dry eye disease: A systematic review and meta-analysis. *Eye.* 2016;30(12):1558–67.
4. Spesialis Ilmu Kesehatan Mata I. Pedoman Nasional Pelayanan Kedokteran (PNPK). 2019.
5. Lee AJ, Lee J, Saw SM, Gazzard G, Koh D, Widjaja D, et al. Prevalence and risk factors associated with dry eye symptoms: A population based study in Indonesia. *Br J Ophthalmol.* 2002;86(12):1347–51.
6. Vehof J, Kozareva D, Hysi PG, Hammond CJ. Prevalence and risk factors of dry eye disease in a british female cohort. *Br J Ophthalmol.* 2014;98(12):1712–7.
7. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. *Ocul Surf.* 2017;15(3):438–510.
8. Gomes JAP, Azar DT, Baudouin C, Efron N, Hirayama M, Horwath-Winter J, et al. TFOS DEWS II iatrogenic report. *Ocul Surf.* 2017;15(3):511–38.
9. Cvenkel B, Štunf Š, Kirbiš IS, Fležar MS. Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma. *Clin Ophthalmol.* 2015;9(1):625–31.
10. Orozco-garcia A, Giorgi-sandoval L, Paczka J, Garcia-y-otero S. Dry Eye Disease Prevalence Exponentially Increases with Age in Patients under Topical Glaucoma Treatment. 2020;61(7):335–47.
11. Baudouin C, Renard JP, Nordmann JP, Denis P, Lachkar Y, Sellem E, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. *Eur J Ophthalmol.* 2013;23(1):47–54.

12. Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial. *Lancet*. 2015;385(9975):1295–304.
13. Negri L, Ferreras A, Iester M. Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life. *J Ophthalmol*. 2019;2019:1–12.
14. Benitez J, Cantu J, Galbis C, D Pinazo M. Ocular Surface Morbidities in Glaucoma. *Eur Ophthalmic Rev*. 2013;07(01):31.
15. Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II Diagnostic Methodology report. *Ocul Surf*. 2017;15(3):539–74.
16. McMonnies CW. Son necesarios mejores métodos de evaluar clínicamente la funcionalidad del mucus. *J Optom*. 2017;10(2):69–70.
17. Baudouin C, Rolando M, Benitez Del Castillo JM, Messmer EM, Figueiredo FC, Irkec M, et al. Reconsidering the central role of mucins in dry eye and ocular surface diseases. *Prog Retin Eye Res*. 2019;71(2018):68–87.
18. Tsubota K, Yokoi N, Shimazaki J, Watanabe H, Dogru M, Yamada M, et al. New Perspectives on Dry Eye Definition and Diagnosis: A Consensus Report by the Asia Dry Eye Society. *Ocul Surf*. 2017;15(1):65–76.
19. Lee D, Agahan A, Verde JE. Effects of Topical Timolol and Latanoprost by Tear Film Evaluation and Impression Cytology. *Ophthalmol Case Reports*. 2017;1(1):8–14.
20. Awe O, Onakpoya O, Adeoye A. Effect of long-term topical antiglaucoma medication use on the ocular surface. *Niger Med J*. 2020;61(4):184.
21. Aydin Kurna S, Acikgoz S, Altun A, Ozbay N, Sengor T, Olcaysu OO. The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: A prospective study. *J Ophthalmol*. 2014;2014:1–8.
22. Salmon JF. KANSKI'S Clinical Ophthalmology Ninth Edition. In: *British Journal of Ophthalmology: a systematic approach*. 9th ed. United Kingdom: Elsevier; 2020. p. 345–421.
23. Cantor L, Rapuano C, Cioffi G. *Fundamentals and Principles of Ophthalmology Section 2*. San Fransisco: America Academy of Ophthalmology. 2014. 213–22 p.

24. Farrand KF, Fridman M, Stillman IÖ, Schaumberg DA. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. *Am J Ophthalmol*. 2017;182(1):90–8.
25. Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II Report Executive Summary. *Ocul Surf*. 2017;15(4):802–12.
26. Thompson N, Isenberg DA, Jury EC, Ciurtin C. Exploring BAFF: Its expression, receptors and contribution to the immunopathogenesis of Sjögren’s syndrome. *Rheumatol (United Kingdom)*. 2016;55(9):1548–55.
27. Peck T, Olsakovsky L, Aggarwal S. Dry eye syndrome in menopause and perimenopausal age group. *J Midlife Health*. 2017;8(2):51–4.
28. Messmer EM. Pathophysiology, diagnosis and treatment of dry eye. *Dtsch Arztebl Int*. 2015;112(5):71–82.
29. Guo OD LW, Akpek E. The negative effects of dry eye disease on quality of life and visual function. *Turkish J Med Sci*. 2020;50(SI2):1611–5.
30. Fine PG. Long-Term Consequences of Chronic Pain: Mounting Evidence for Pain as a Neurological Disease and Parallels with Other Chronic Disease States. *Pain Med*. 2011;12(7):996–1004.
31. Karakus S, Mathews PM, Agrawal D, Henrich C, Ramulu PY, Akpek EK. Impact of Dry Eye on Prolonged Reading. *Optom Vis Sci*. 2018;95(12):1105–13.
32. Masmali AM, Purslow C, Murphy PJ. The tear ferning test: A simple clinical technique to evaluate the ocular tear film. *Clin Exp Optom*. 2014;97(5):399–406.
33. Nebbioso M, Sacchetti M, Bianchi G, Zicari AM, Duse M, Del Regno P, et al. Tear ferning test and pathological effects on ocular surface before and after topical cyclosporine in vernal keratoconjunctivitis patients. *J Ophthalmol*. 2018;2018(2):1–11.
34. Kumar P, Bhargava R, Kumar M, Ranjan S, Kumar M, Verma P. The correlation of routine tear function tests and conjunctival impression cytology in dry eye syndrome. *Korean J Ophthalmol*. 2014;28(2):122–9.

35. Swathi Nagarajan MPN, Kavitha N. Detecting ocular surface changes associated with soft contact lens wear using conjunctival. *J Clin Ophthalmol Res.* 2018;6(3):117–20.
36. Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II Management and Therapy Report. *Ocul Surf.* 2017;15(3):575–628.
37. Robert N. Weinreb, MD, Tin Aung, MD, PhD, and Felipe A. Medeiros, MD P. The Pathophysiology and Treatment of Glaucoma. *Nat Sel Soc Behav* (Eds R D Alexander D W Tinkle), Chiron Press New York. 2014;311(18):363–81.
38. King A, Azuara-Blanco A, Tuulonen A. Glaucoma. *BMJ.* 2013;346(7912):1–9.
39. Schmidl D, Schmetterer L, Garhöfer G, Popa-Cherecheanu A. Pharmacotherapy of Glaucoma. *J Ocul Pharmacol Ther.* 2015;31(2):63–77.
40. Vohra R, Tsai JC, Kolko M. The Role of Inflammation in the Pathogenesis of Glaucoma. *Surv Ophthalmol.* 2013;58(4):311–20.
41. Riordan P, Whitcher JP. *Vougan&Asbury Oftalmologi Umum.* In: 17th ed. Jakarta: EGC; 2015. p. 1–228.
42. European Glaucoma Society. Terminology and Guidelines for Glaucoma: Treatment principles and options (Chapter 3). *Br J Ophthalmol.* 2017;101(6):130–95.
43. Amrayni M, Gustianty E, Heryati S, Mata P, Rs N, Cicendo M. Perbandingan Gambaran Sitologi Permukaan Okular Pascapemberian Tetes Mata Tanpa Pengawet Golongan Timolol Maleat 0,5%, Latanoprost 0,005% dan Fixed Combination pada Penderita Glaukoma. 2016;1(1):1–7.
44. Mäenpää J, Pelkonen O. Cardiac safety of ophthalmic timolol. *Expert Opin Drug Saf* [Internet]. 2016;15(11):1549–61. Available from: <http://dx.doi.org/10.1080/14740338.2016.1225718>
45. Contreras-Ruiz L, Ghosh-Mitra A, Shatos MA, Dartt DA, Masli S. Modulation of conjunctival goblet cell function by inflammatory cytokines. *Mediators Inflamm.* 2013;2013.

46. Lee SY, Wong TT, Chua J, Boo C, Soh YF, Tong L. Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity. *Eye*. 2013;27(10):1142–50.
47. Firat PG, Samdanci E, Doganay S, Cavdar M, Sahin N, Gunduz A. Short-term effect of topical brinzolamide-timolol fixed combination on ocular surface of glaucoma patients. *Int J Ophthalmol*. 2012;5(6):714–8.
48. Key A, Sch T, Med JA, Pophali S, Tiple C. *Scholars Journal of Applied Medical Sciences (SJAMS)* Ocular Surface Disease Related to Prostaglandin Analogue with Benzalkonium Chloride versus Prostaglandin Analogue with Stabilized Oxy Chloride Complex in Glaucoma Patients. *Sch J Appl Med Sci*. 2018;4(6):4848–55.
49. Sugiyono. *Metode Penelitian Kuantitatif, Kualitatif, dan R&D*. In: Alfabeta. Bandung; 2017. p. 380.
50. Nursalam. *Metodelogi Penelitian Ilmu Keperawatan*. Selemba Medika. 2017. 454 p.
51. Parsiska A. Hubungan Faktor Risiko dengan Glaukoma Primer pada pasien di Poliklinik Mata RSUP Dr. M. Djamil Padang. *Scholar Unand*. Universitas Andalas; 2017.
52. Putra Deva GA, Kusumadjaja NMAS, Agus IM. Prevalensi Glaukoma Sudut Terbuka Primer di RSUP Sanglah Periode Juni 2017 - Juni 2018. *J Med Udayana*. 2020;9(4):1689–99.
53. Khawaja AP, Chan MPY, Garway-Heath DF, Broadway DC, Luben R, Sherwin JC, et al. Associations with retinal nerve fiber layer measures in the EPIC-Norfolk eye study. *Investig Ophthalmol Vis Sci*. 2013;54(7):5028–34.
54. Zhang N, Wang J, Li Y, Jiang B. Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. *Sci Rep*. 2021;11(1):1–12.
55. Pasquale LR, Rosner BA, Hankinson SE, Kang JH. Attributes of female reproductive aging and their relation to primary open-angle glaucoma: A prospective study. *J Glaucoma*. 2017;16(7):598–605.

56. Newman-Casey PA, Talwar N, Nan B, Musch DC, Pasquale LR, Stein JD. The potential association between postmenopausal hormone use and primary open-angle glaucoma. *JAMA Ophthalmol.* 2014;132(3):298–303.
57. Kemenkes RI. infoDatin Glaukoma 2019. 2019. p. 1–9.
58. Ilahi F, Vera V. Tampilan Klinis pada Glaukoma Primer Sudut Terbuka di RSUP DR M Djamil Padang. *J Kesehat Andalas.* 2018;7(Supplement 1):1.
59. Bhardwaj V, Rajeshbhai GP. Axial length, anterior chamber depth-a study in different age groups and refractive errors. *J Clin Diagnostic Res.* 2013;7(10):2211–2.
60. Sunarto E. Karakteristik Pasien Glaukoma di Rumah Sakit Umum Pusat Haji Adam Malik Medan Tahun 2016-2017. 2018;1–35.
61. Chan EWE, Li X, Tham YC, Liao J, Wong TY, Aung T, et al. Glaucoma in Asia: Regional prevalence variations and future projections. *Br J Ophthalmol.* 2016;100(1):78–85.
62. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. *Ophthalmology.* 2014;121(11):2081–90.
63. Xing Y, Zhu L, Zhang K, Huang S. The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis. *PLoS One* [Internet]. 2020;15(2):1–15. Available from: <http://dx.doi.org/10.1371/journal.pone.0229682>
64. Mustofa A, Ulfa NM, Suryandari M. Profil Pereseapan Penyakit Mata Glaukoma pada Pasien BPJS Rawat Jalan (Studi dilaksanakan di RS Mata Masyarakat JawaTimur Periode Januari - Desember 2015). *J Pharm Sci.* 2018;1(1):27–33.
65. Barisic F. Prevalence of Ocular Surface Disease in Patients with Glaucoma using Topical Antiglaucoma Medications. *J Clin Exp Ophthalmol.* 2014;5(2):1–5.

66. Katz G, Springs CL, Craven ER, Montecchi-Palmer M. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. *Clin Ophthalmol.* 2010;4(1):1253–61.
67. Garcia-Feijoo J, Sampaolesi JR. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. *Clin Ophthalmol.* 2012;6(1):441–6.
68. Singh AK, Nagpal S, Tyagi R. A study of tear ferning patterns in elderly individuals with dry eye disorder. *J Clin Diagnostic Res.* 2018;12(5):NC01–4.
69. Tiedemann D, Mouhammad ZA, Utheim TP, Dartt DA, Heegaard S, Petrovski G, et al. Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment. *J Glaucoma.* 2019;28(4):325–33.
70. Zhu W, Kong X, Xu J, Sun X. Effects of Long-Term Antiglaucoma Eye Drops on Conjunctival Structures: An in Vivo Confocal Microscopy Study. *J Ophthalmol.* 2015;2015.
71. Kumar R, Kaur I, Kaur P. Effect of Topical Antiglaucoma Drugs on Tear Film in Human Eyes. *IOSR J Dent Med Sci Ver I.* 2015;14(10):2279–861.
72. Cennamo G, Forte R, Del Prete S, Cardone D. Scanning electron microscopy applied to impression cytology for conjunctival damage from glaucoma therapy. *Cornea.* 2013;32(9):1227–31.

